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Abstract. For over 60 years, pentavalent antimony (Sbv) has been the first-line treatment of leishmaniasis. Sickle cell
anemia is a disease caused by a defect in red blood cells, which among other things can cause vasooclusive crisis. We
report the case of a 6-year-old child with leishmaniasis who during treatment with meglumine antimoniate developed a
sickle cell crisis (SCC). No previous reports describing the relationship between antimonial drugs and sickle cell disease
were found. Reviews of both the pathophysiology of SCC and the mechanism of action of Sbv revealed that a common
pathway (glutathione) may have resulted in the SCC. ChemoText, a novel database created to predict chemical-protein-
disease interactions, was used to perform a more expansive and systematic review that was able to support the association
between glutathione, Sbv, and SCC. Although suggestive evidence to support the hypothesis, additional research at the
bench would be needed to prove Sbv caused the SCC.
INTRODUCTION
Leishmaniasis is a disease caused by the parasite Leishmania
and transmitted by sand flies from the genus Lutzomyia. It
may affect the skin, mucosal surfaces, or the viscera. Viannia
is the predominant subgenus in Colombia with the species
Leishmania panamensis, Leishmania braziliensis, and Leishmania
guyanensis being most prevalent.1 Cutaneous leishmaniasis
has a wide distribution throughout Colombia with the south-
ern Pacific Colombian coast being historically endemic. The
population is mainly of Afro-Colombian heritage and access
to health services is difficult. The Sbv continues to be the
first line of treatment. Second line options include milte-
fosine, amphotericin B, and pentamidine among others.
Side effects of meglumine antimoniate (MA) have included
constitutional symptoms, renal failure, hepatotoxicity, cardio-
toxicity, and pancreatitis.2
Sickle cell anemia (SCA) is a hereditary disease caused
by the mutation of a nucleotide at the sixth position of the
b-globin chain provoking the replacement of the amino acid
glutamate by valine. This change facilitates a hemoglobin
polymerization setting off the characteristic sickle deformity
of the red blood cells (RBC). This structural alteration is
accompanied, among other consequences, by cellular rigidity
and an increased adherence to vascular endothelium. Ulti-
mately, vasooclusion occurs generating a painful crisis and
damage to target organs. The half-life of RBCs is also dimin-
ished without the bone marrow being able to supply the RBC
demand leading to anemia.3 The SCA has a higher prevalence
in the Afro-descendent population and in the Colombian
southern pacific region, prevalence is estimated between 10%
and 18%.4
No prior reports of interactions between these two dis-
eases or their treatments could be found in the medical liter-
ature. ChemoText is a recently described database and data
mining approach that can be used to investigate hypothetical
chemical-protein-disease relationships based on MeSH term
co-annotations in the literature.5 We describe a patient with
both SCA and leishmaniasis. We then use both manual liter-
ature search methods and ChemoText analysis to explore
hypothetical mechanisms underlying the potential pathophys-
iological cause of a sickle cell crisis (SCC) coincident tempo-
rally with treatment of his leishmaniasis.
Background clinical case observation. A 6-year-old Afro-
Colombian male, from the rural area of Tumaco (Nariño –
Colombia) presented with two ulcerated lesions on his right
ear of 6 months duration (Figure 1). Leishmania amastigotes
where identified in the direct microscopic examination of
tissue smears.
His past medical history included anemia (hemoglobin
level of 8.3 g/dL) and a hospitalization at 4 years of age with
fever and knee pain.
With the diagnosis of cutaneous leishmaniasis, MA was
started at a dose of 20 mg/kg/d intramuscular for 20 days as
established by the protocol of the Colombian Ministry of
Social Protection. Before administration of the first dose a
hemoglobin level of 8.8 g/dL was documented. Three days
after the treatment was started the patient presented to the
emergency service complaining of abdominal pain associated
with diarrhea without fever. He was hospitalized and MA
was suspended. Gastroenteritis was suspected therefore a
coprologic exam and urinalysis was performed. Ceftriaxone
treatment was started. During hospitalization, pain in the
lower limbs was reported and splenomegaly was confirmed
by abdominal ultrasound. The results of the urinalysis and
coprologic exam ruled out an infectious process. His hemo-
globin level had decreased to 6.8 g/dL and a peripheral blood
smear showed moderate hypochromia, anisocytosis, micro-
cytosis, poikylocytosis, koilocytes, and acanthocytes. The
sodium metabisulfate test (for sickle cell trait) was positive.
With this result, and the absence of an infectious process to
explain the symptoms, the diagnosis of SCC was made. Folic
acid was started and the patient was discharged eventually in
good condition and without pain.
Hemoglobin electrophoresis revealed hemoglobin F =
20.7%, hemoglobin S = 74.3%, and a band compatible with
hemoglobin A2 = 5.1%. No blood transfusion had been
received in the previous 3 months. This confirmed the patient
as homozygous for sickle cell disease.
Once the SCC was overcome, the patient’s lesions were
noted to have significant improvement (Figure 2). Therefore,
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no additional treatment was administered. The lesions, how-
ever, never fully recovered after 12 months of follow-up and
miltefosine was administered at a dose of 2.4 mg/kg/day for
28 days (Figure 3). At the end of the treatment, lesions had
resolved and no recurrence was observed after 3 months of
follow-up. During the same period no other SCC occurred
(Figure 4).
Results of manual search and automated literature mining.
The patient’s clinical presentation and the hemoglobin elec-
trophoresis established the diagnosis of SCA. The coin-
cidence of the treatment administration with the episode
of SCC raised the question of a possible causal relationship.
A manual literature search was conducted through PubMed
and LILACS (last search on July 2011). Using “AND”
combinations of all search terms, no prior reports were
found. We also consulted with experts in hematology and in
the treatment and clinical management of leishmaniasis.
Expert consultants also had no obvious explanation. The
second step was a thorough review of the pathophysiology
of SCC together with the mechanism of action of Sbv in
search of a possible interaction. As a result of these dis-
cussions and research, the glutathione pathway captured
our interest.
The role of redox imbalance has been described in the
pathophysiology of SCC. Physiologically RBCs are exposed
to an elevated oxidative stress. In the case of sickle cell
patients, RBCs undergo even higher levels of oxidative
stress6; to counteract this situation, RBCs possess diverse
antioxidant molecules that allow them to achieve homeo-
stasis. Glutathione is part of the antioxidant system and has
been considered the principal buffer thiol of redox reactions
inside the RBC.7 This system has been studied in erythro-
cytes of individuals with SCA and its role in the patho-
physiology has been characterized. Glutathione levels in the
RBCs of patients with SCA are diminished when compared
with healthy controls. This decrease occurs despite a higher
Figure 2. Lesions after treatment with meglumine antimoniate.
Figure 1. Lesions previous to treatment withmeglumine antimoniate. Figure 3. Lesions after 1 year of follow-up, previous to treatment
with miltefosine.
Figure 4. Lesions after treatment with miltefosine.
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rate of production, indicating that the defect does not reside
in the antioxidant production but in an elevated consump-
tion caused by the great oxidative stress to which the cell is
submitted.7–10 Low glutathione levels have also been associ-
ated with hemolysis probably explaining why antioxidant ther-
apies developed to target the glutathione pathway have had
good results.11,12 By the same logic, the supplementation with
precursors such as L-glutamine successfully diminish the phe-
nomenon of endothelial adhesion.12,13
Table 1
Proteins that have been co-annotated in PubMed articles with MeSH
terms Anemia, Sickle Cell, AND (Meglumine Antimoniate OR
Antimony Sodium Gluconate OR Antimony) and the number of












1 0 1 0
5-Aminolevulinate
synthetase
2 0 0 1
Acetylcholinesterase 2 0 0 1
Acetylcysteine 3 0 0 1
Acid phosphatase 6 0 0 1
Adenosine
triphosphatases
14 0 0 7
Adrenocorticotropic
hormone
4 0 0 1
Alkaline phosphatase 25 1 2 3
Aminobutyric acids 1 0 0 1
Amylases 1 2 3 0
Antilymphocyte serum 2 0 0 1
Antiporters 2 0 0 1
Buthionine sulfoximine 1 1 1 1
Ca(2+) Mg(2+)-ATPase 10 0 0 1
Calcium channels 1 0 0 1
Calcium-transporting
ATPases
19 0 0 1
Catalase 8 0 0 2
Cholinesterases 3 0 0 1
Collagen 14 0 0 1
C-reactive protein 14 1 0 1
Creatine kinase 1 0 1 1
Cysteine 14 0 1 8
DNA-binding proteins 8 0 2 2
DNA-directed
DNA polymerase
4 0 0 5
DNA-directed
RNA polymerases
1 0 0 2
Endonucleases 2 0 0 1
Erythropoietin 74 0 1 0
Ether-A-Go-Go
potassium channels
1 0 0 1
Glucuronidase 6 0 0 2
Glutamates 9 0 0 2
Glutathione 31 1 2 7
Glutathione peroxidase 8 0 0 2
Glutathione reductase 6 0 1 1
Glutathione transferase 2 0 2 1
Glycoside hydrolases 2 0 0 1
Granulocyte-macrophage
colony-stimulating factor
12 0 3 0
Heme oxygenase
(decyclizing)
1 0 0 3
Heme oxygenase-1 4 0 1 1
Hemoglobins 639 1 4 4
Hexokinase 8 0 1 0
Histones 2 0 0 1
HMOX1 protein, human 2 0 1 1
HSP70 heat-shock proteins 2 0 0 1
Hydrolases 1 0 0 1
Immunoglobulin A 24 1 1 0
Immunoglobulin G 61 3 5 3
Immunoglobulin M 36 2 1 0
Interferon-gamma 6 5 8 1
Interferons 1 0 1 2
Interleukin-1 6 0 1 0
Interleukin-10 3 4 2 0
Interleukin-2 3 1 1 2
Interleukin-3 8 0 1 0













Interleukin-6 11 0 1 0
Lactoferrin 2 0 0 1
Lectins 3 1 0 0
Lectins, C-type 1 0 0 1
L-lactate dehydrogenase 22 0 1 1
Methionine 11 0 0 2
Mitogen-activated
protein kinases
2 0 1 0
NAD 10 0 0 3
NADH, NADPH
oxidoreductases
1 0 0 1
Neuraminidase 3 0 0 1
Nitric oxide synthase 22 0 1 1
Nitric oxide synthase
type II
10 0 2 0
Nos2 protein, mouse 4 0 1 0
Oxidoreductases 3 0 1 4
Penicillamine 1 0 0 2
Peroxidase 7 0 0 1
Peroxidases 5 0 0 1
Phosphofructokinase-1 3 0 1 4
Phosphoprotein
phosphatases
3 0 1 0
Phosphotransferases 5 0 0 1
Phytohemagglutinins 6 0 1 0
Porphobilinogen synthase 3 0 0 1
Proline 1 0 0 1
Protein tyrosine
phosphatases
2 0 4 1
Protein-tyrosine kinases 4 0 1 0
Proteoglycans 2 0 1 0
Purine-nucleoside
phosphorylase
1 0 0 1
Pyruvate kinase 14 0 1 0
Receptors, IgG 3 0 1 0
Receptors, immunologic 6 0 0 1
Receptors, tumor
necrosis factor
1 0 1 0
Repressor proteins 1 0 0 1
Ribonucleo proteins 1 0 0 1
RNA-directed
DNA polymerase
1 0 0 3
Serine 6 0 0 1
Serine endopeptidases 1 0 1 0
Superoxide dismutase 12 0 0 3
Transferrin 35 0 0 1
Transforming growth
factor-b
2 0 1 0
Trypsin 17 0 0 1
Tuftsin 2 0 1 0
Tumor necrosis
factor-a
22 3 0 2
Tyrosine 13 0 1 0
Urease 2 0 0 1
*The proteins were defined as any annotations mapping to the MeSH Tree level D12
(http://www.nlm.nih.gov/mesh). The version of ChemoText used was built from baseline
2010 MEDLINE.
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Although the mechanism of action of Sbv is not yet fully
understood, one pathway that has been described involves
antioxidants of the thiol group. It has been shown that Sbv
in its trivalent form (active molecule) depletes glutathione
and tripanothione levels of parasites of Leishmania
donovani probably through an efflux system. Additionally,
Sbv has the capacity to inhibit both the tripanothione reduc-
tase enzyme of the parasite and also human RBC gluta-
thione reductase.14,15 Finally, Sbv exerts the same action
on human macrophages suggesting Sbv could be a chemo-
therapeutic agent for neoplasias, such as acute promye-
locytic leukemia.16
The published literature thus supports the hypothesis that
Sbv could potentially trigger an SCC. The hypothetical mech-
anism would be an alteration in the redox balance in RBCs
of patients that are facing an even greater oxidative stress
caused by their disease. After uncovering this possible explan-
atory pathway we sought to expand our review of potential
interactions using ChemoText, a multivariate search tool
designed to investigate possible chemical-protein-disease rela-
tionships. We attempted to compare and contrast our results
with those generated by the ChemoText automated literature
mining tool. At the outset, we hypothesized that the exercise
might validate our ideas about glutathione and indicate other
potential pathways linking sickle cell and Sbv.
The goal of the ChemoText analysis was to find proteins
implicated in both the mechanism of action behind anti-
mony drugs and the physiology of SCA. We first queried
ChemoText for all protein annotations occurring in articles
where the chemical annotations Meglumine Antimoniate,
Antimony Sodium Gluconate, or Antimony were present
and the drugs were the subject of the article. Next, we
queried ChemoText for all protein annotations co-occurring
in articles with the disease annotation Anemia, Sickle Cell.
These queries resulted in four sets of proteins that were
then evaluated to find the overlapping entries. After refin-
ing the list to include only proteins with meaningful speci-
ficity (i.e., removal of non-specific protein terms like Blood
Proteins), 98 proteins remained. These proteins are listed in
Table 1 along with the number of published articles in
which they are annotated both with the antimonial drugs
and with SCA. In support of our earlier findings by manual
search, glutathione and its associated enzymes were also
detected by ChemoText. Glutathione itself has been anno-
tated in 31 articles about SCA, and in articles about each of
the antimonial drugs.
DISCUSSION
The results presented here describe a potential relationship
between SCC and MA and highlight the need for thoughtful
consideration of unknown relationships between chemicals,
proteins, and diseases. This one interaction will require addi-
tional research at the bench to determine if there is a true
causative link between the drug and the crisis. However, the
comparison of a manual search with automated literature
mining for underlying mechanistic connections, illustrates the
potential for high throughput data mining to identify poten-
tially important pathways. ChemoText independently con-
firmed our findings about the glutathione pathway. Even more
interesting was discovering the number of biochemical and
molecular pathways relating to antimonial drugs and sickle
cell pathophysiology. Although the mechanistic connections
identified by manual search and ChemoText are purely spec-
ulative at this stage, these results open the door for additional
theoretical evidence to be discovered and investigated.
Literature mining or text mining has been used by a num-
ber of researchers to extract and organize known relation-
ships between biomedical entities, and to use those known
relationships to predict or infer new relationships. Using such
text-based inference, researchers have predicted new thera-
pies for disease, novel applications of existing drugs, and
connections between diseases.5,17–20
ChemoText was constructed by extracting the MeSH
annotations from each article in MEDLINE, the database
behind the National Library of Medicine’s PubMed. The
annotations were processed and organized into a database
that allows known relationships between chemicals, proteins,
and disease to be explored and new relationships to be
inferred. (A publicly accessible version of ChemoText is
under development and available to the public at http://
chembench-dev.mml.unc.edu:8082). There are other data
repositories containing combinations of chemical, disease,
and protein information, including STITCH, CBioC, KEGG,
DrugBank, and the Comparative Toxicogenomics Data-
base.21–25 Whereas many of these sources are curated, the data
in ChemoText is extracted automatically from MEDLINE
and receives no curation. Although the quality of the data in
ChemoText may not rival the curated sources, ChemoText
has greater coverage of the literature, reflecting the broad
reach of PubMed.
In earlier work using ChemoText in drug research, explicit
relationships between diseases and proteins were used to
infer new, possibly therapeutic, relationships between chem-
icals and diseases.5 In the current study, we took a slightly
different approach and found the overlap between the set of
proteins related to sickle cell in the literature and the pro-
teins related to antimony drugs in the literature. The list of
overlapping proteins has the potential to suggest possible
mechanisms in common between the activity of MA and the
pathology of SCC.
Despite these search results, a causal link between MA
and SCC is clearly not known. The effect of the drug has
been demonstrated in vitro and it is not known if the same
action occurs in vivo. Furthermore, ChemoText was able to
find potentially important disease-protein-drug relationships;
however, because a correlation cannot be established by a
single case, one must consider that this outcome could have
been a random event. It would therefore be important, on
the basis of theoretical findings and advanced data mining
technologies, to perform a more thorough case-controlled
investigation or more mechanistic studies in vitro. Addressing
these hypothetical interactions would allow physicians to offer
better therapeutic options in certain populations where both
diseases coexist.
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